| Serial Number | 79290136 |
| Word Mark | NOAELPLATIN |
| Filing Date | Tuesday, June 16, 2020 |
| Status | 404 - IR CANCELLED - US REGISTRATION CANCELLED |
| Status Date | Friday, June 3, 2022 |
| Registration Number | 6398898 |
| Registration Date | Tuesday, June 29, 2021 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 13, 2021 |
| Goods and Services | Pharmaceutical preparations for the treatment of pancreatic tumors; pharmaceutical agents for the treatment of disorders in sensory organs; thyroid and para-thyroid hormone preparations; medicinal tonics for the treatment of pancreatic tumors; oral contraceptive pills; antiemetics; local anesthetics; bronchodilating preparations; anti-cough drops; androgen preparations; pituitary hormone preparations; pharmaceutical preparations for treating diabetes; pharmaceutical agents for use in regulating metabolism; vaccines against flu; chilblain preparations; pharmaceutical preparations for headache; anesthetics; pharmaceutical for use in the treating disorders of the peripheral nervous system; pharmaceutical preparations for immunity adjustment; nutritive substances for microorganisms for medical purposes; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations for treating disorders of the urogenital organs; vitamin preparations; pharmaceutical preparations for the treatment of bone diseases; anti-inflammatory and antipyretic preparations; pharmaceutical agents for treating disorders of the digestive organs; pharmaceutical preparations for the treatment of cardiovascular disorders; nervines; ophthalmic preparations; allergy medications; chemico-pharmaceutical preparations for the treatment of pancreatic disorders; medicines for the treatment of gastrointestinal diseases; mineral injection preparations featuring vitamin supplements for medical purposes; antioxidants for medical purposes; haematogen; pharmaceutical preparations for tumor treatment; multivitamin preparations; laxative suppositories; pharmaceutical preparations for use in the treatment of disorders of the central nervous system; pharmaceutical preparations for diagnosis of cancer; sedatives; analgesics; vaginal washes for medical purposes; pharmaceutical preparations for treating asthma; medicines for treating tooth pain; hemorrhoid preparations; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; vaccines against pneumococcal infections; dermatological pharmaceutical products; contraceptive preparations; antihypertensives; anti-uric preparations; anti-diabetic pharmaceuticals; pharmaceutical preparations for treatment of hemorrhoids; antibiotic preparations; antibiotics; anti-cancer preparations; anti-cancer treatment supplements; antidepressants; anticoagulants; antineoplastics; anti-dermoinfectives; antidotes; antipyretic analgesics; febrifuges; vasoconstrictors; hypoglycemic agents; blood solvent being preparations for treating blood disorders; pharmaceutical preparations for treating disorders of the respiratory organs; respiratory stimulant preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for treating respiratory diseases and asthma; mixed vitamin preparations; preparations for the treatment of burns; disinfectants for chemical toilets; chemotherapeutics; preparations for treatment of hepatitis; preparations for treating colds; preparations for the treatment of hyperlipidemia; preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of osteoporosis; preparations for the treatment of osteoporosis; injectable pharmaceuticals for treatment of anaphylactic reactions; pharmaceutical preparations for treating halitosis; nausea treatment preparations; antiulcerants; pharmaceutical preparations for the treatment of musculoskeletal disorders; preparations for the treatment of muscle fatigue; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for the treatment of rhinitis; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; pharmaceutical preparations for the treatment of cancerous cells; medicines for treating intestinal disorders; cardiovascular treatment preparations; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for treating allergies; pharmaceutical preparations and compositions for the treatment and prevention of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; medicated preparations for the treatment of mouth disorders; transdermal patches for medical treatment of nausea; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of gout; drug delivery agents in the form of dissolvable films, coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents consisting of compounds that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | H - NOT AVAILABLE |
| Class Status Date | Friday, March 4, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CnPharm Co., Ltd. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | CnPharm Co., Ltd. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | CnPharm Co., Ltd. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Sunday, March 20, 2022 | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED |
| Sunday, March 20, 2022 | DEATH OF INTERNATIONAL REGISTRATION |
| Tuesday, November 23, 2021 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Thursday, October 28, 2021 | FINAL DISPOSITION NOTICE SENT TO IB |
| Thursday, October 28, 2021 | FINAL DISPOSITION PROCESSED |
| Wednesday, September 29, 2021 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Friday, September 3, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Monday, July 12, 2021 | REVIEW OF CORRESPONDENCE COMPLETE - CERTIFICATE OF REG MAILED |
| Tuesday, June 29, 2021 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, May 19, 2021 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Tuesday, April 13, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 13, 2021 | PUBLISHED FOR OPPOSITION |
| Monday, April 12, 2021 | NOTIFICATION PROCESSED BY IB |
| Wednesday, March 24, 2021 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, March 24, 2021 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, March 24, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, March 9, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, March 4, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, March 4, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, March 2, 2021 | ASSIGNED TO LIE |
| Tuesday, December 1, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Sunday, November 8, 2020 | REFUSAL PROCESSED BY IB |
| Wednesday, October 21, 2020 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Wednesday, October 21, 2020 | REFUSAL PROCESSED BY MPU |
| Thursday, September 24, 2020 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, September 23, 2020 | NON-FINAL ACTION WRITTEN |
| Friday, September 18, 2020 | ASSIGNED TO EXAMINER |
| Tuesday, July 28, 2020 | APPLICATION FILING RECEIPT MAILED |
| Friday, July 24, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Thursday, July 23, 2020 | SN ASSIGNED FOR SECT 66A APPL FROM IB |